Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmacies.

Details

Ressource 1Download: AJHP_Fingo.pdf (713.30 [Ko])
State: Public
Version: Author's accepted manuscript
License: Not specified
Serval ID
serval:BIB_D9580C267D8B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmacies.
Journal
American journal of health-system pharmacy
Author(s)
Bourdin A., Schluep M., Bugnon O., Berger J.
ISSN
1535-2900 (Electronic)
ISSN-L
1079-2082
Publication state
Published
Issued date
18/07/2019
Peer-reviewed
Oui
Volume
76
Number
15
Pages
1150-1157
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
The development and dissemination of a specialty pharmacy service to optimize fingolimod therapy management are described.
Fingolimod was the first oral therapy developed to counter relapsing-remitting multiple sclerosis. Pharmacovigilance measures and individualized support are strongly recommended due to associated safety concerns. The Fingolimod Patient Support Program (F-PSP) was developed and disseminated within a community pharmacy network. The F-PSP aims to ensure responsible use of fingolimod and patient empowerment by promoting medication adherence and patient safety through a person-centered and integrated care approach. It complements basic pharmacy services through 2 interventions: medication adherence support and pharmacovigilance tailored to fingolimod. The adherence intervention combines motivational interviewing with longitudinal electronic medication adherence monitoring. The pharmacovigilance component consists of informing patients of fingolimod recommendations, reminding patients of recommended medical tests, and tracking and monitoring symptoms, especially those of potential serious adverse fingolimod reactions. A secure Web platform guides the pharmacist in conducting interviews and enables collection of patient-reported outcome data. A transition care pharmacist proposes program participation to all patients initiated on fingolimod, performs enrollment, and coordinates transfers to patient-designated community pharmacies for ongoing care.
The F-PSP enables support of individual patients, and also provides real-world data, helping to bridge the gap between practice and research. The F-PSP is intended to be a generic model of a specialty pharmacy service that is transferable to any other healthcare context, specialty drug or disease.
Keywords
Administration, Oral, Community Networks/organization & administration, Community Pharmacy Services/organization & administration, Delivery of Health Care, Integrated/organization & administration, Female, Fingolimod Hydrochloride/therapeutic use, Humans, Medication Adherence/psychology, Medication Therapy Management/organization & administration, Motivational Interviewing, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Patient Education as Topic, Patient Safety, Patient Transfer/organization & administration, Pharmacists/organization & administration, Pharmacovigilance, Program Development, Switzerland, medication adherence, patient safety, patient support program, patient-centered care, pharmacovigilance, specialty pharmacy services
Pubmed
Web of science
Create date
30/06/2019 14:58
Last modification date
09/11/2023 7:22
Usage data